Welcome to this UK AstraZeneca produced and funded website

This website is intended for UK Healthcare Professionals only.

 

The website contains both promotional and non-promotional content.

 

If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk

 

For any other UK residents please visit astrazeneca.co.uk

I am not a Healthcare Professional
IMFINZI (durvalumab) UK Prescribing Information
IMJUDO (tremelimumab) ▼ UK Prescribing Information
Adverse Event Reporting

This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk

AstraZeneca-logo
  • Our Medicines
    • Cardiovascular, Renal & Metabolism
      • ATTR Amyloidosis
        • WAINZUA®▼(eplontersen)
      • Chronic Kidney Disease (CKD)
        • FORXIGA® (dapagliflozin)
      • Heart Failure
        • FORXIGA® (dapagliflozin)
      • Hyperkalaemia
        • LOKELMA® (sodium zirconium cyclosilicate)
      • Type 2 Diabetes (T2D)
        • FORXIGA® (dapagliflozin)
    • Oncology
      • Breast Cancer
        • LYNPARZA® (olaparib)
        • TRUQAP®▼(capivasertib)
      • Bladder Cancer
        • IMFINZI® (durvalumab)
      • Endometrial Cancer
        • IMFINZI® (durvalumab)
        • LYNPARZA® (olaparib)
      • Gastrointestinal Cancer
        • IMFINZI® (durvalumab)
        • IMJUDO®▼(tremelimumab)
      • Lung Cancer
        • IMFINZI® (durvalumab)
        • TAGRISSO® (osimertinib)
      • Ovarian Cancer
        • LYNPARZA® (olaparib)
      • Prostate Cancer
        • LYNPARZA® (olaparib)
        • ZOLADEX® (goserelin)
    • Respiratory
      • Asthma
        • TEZSPIRE®▼ (tezepelumab)
        • SYMBICORT® (budesonide/formoterol)
      • Chronic Obstructive Pulmonary Disease(COPD)
        • TRIXEO AEROSPHERE® (formoterol fumarate dihydrate/glycopyrronium/budesonide)
        • BEVESPI® (glycopyrronium/formoterol fumarate dihydrate)
    • Vaccines
      • Flu
        • FLUENZ® nasal spray suspension (influenza vaccine, live attenuated, nasal)
  • Therapy Areas
    • Cardiovascular, Renal & Metabolism
      • ATTR Amyloidosis
      • Chronic Kidney Disease (CKD)
      • Heart Failure
      • Hyperkalaemia
      • Type 2 Diabetes (T2D)
    • Oncology
      • Breast Cancer
      • Bladder Cancer
      • Endometrial Cancer
      • Gastrointestinal Cancer
      • Lung Cancer
      • Ovarian Cancer
      • Prostate Cancer
    • Respiratory
      • Asthma
      • Chronic Obstructive Pulmonary Disease(COPD)
    • Vaccines
      • Flu
  • About us
    • AZ Commitment
  • Contact us
  • AstraZeneca UK
  • IMFINZI (durvalumab)
  • Resources
  • The five pillars of imAE management
  • Home
  • Biliary tract cancer
    • About biliary tract cancer
    • Mode of action
    • TOPAZ-1 clinical trial
    • Dosing & administration
    • Resources
  • Hepatocellular carcinoma
    • Why STRIDE?
    • About hepatocellular carcinoma
    • Mode of action
    • HIMALAYA clinical trial
    • Dosing & administration
    • Resources
  • Resources
    • Biliary tract cancer resources
    • Hepatocellular carcinoma resources
    • Gastrointestinal cancer resources
The five pillars of imAE management

< Back to resources

Watch Dr Dan Patterson discuss the five pillars of immune-mediated adverse events (imAE) management.

Five pillars of immunotherapy management

In this video, Dr Dan Patterson gives an overview of the five pillars of immunotherapy management: prevention, anticipation, detection, treatment and monitoring. He also highlights key factors to consider at each stage.

GB-63685 | May 2025

Connessiallasalute.it

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Terms of use

Privacy Policy

Cookie Policy

Contact Us

LinkedIn

Twitter

©2026 AstraZeneca. GB-76920 | May 2026

Enhance your knowledge, stay informed

Be the first to know. Hear about events, products and ways to support your patients.

Thank you. We will be in touch

GB-74216| DOP : February 2026